CompanyGraphAt a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- ScaleMarket cap is $32.02B, higher than 95% of all stocks globally
- PositionReturn on equity is 24.3%, higher than 95% of its Medical Instruments & Supplies peers (median 5.7%)
- Interpretations11 currently firing — 1 · 10
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.19%Above 5Y avg (0.88%)
Annual Rate
USD 2.64Paid quarterly
Payout Ratio
23.0%Sustainable
Consecutive Growth
13 yrStrong track record
Paying Dividends
15 yr
Payback Period
89.0 yr
Last Ex-Dividend
Aug 20, 2026
Last Payment
Sep 24, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
Long Dividend Streak With Three-Year FCF Coverage
→dividend consistency
dividend coverage and payment stability
ratio cashflow fcf conversion
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
Long Dividend Streak With Three-Year FCF Coverage
Years of uninterrupted dividends, covered by free cash flow on a three-year average.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
32.02BUSDvs all stocks (USD)
Trailing P/E
21.28xvs Medical Instruments & Supplies peers
Revenue (TTM)
5.65BUSDvs all stocks (USD)
Profit Margin
26.95%vs Medical Instruments & Supplies peers
Beta
0.7660xvs all stocks
52-Week Change
-18.10%vs all stocks
Forward Annual Dividend Yield
1.19%vs all stocks
Market Capitalization
32.02BUSDvs all stocks (USD)
Enterprise Value
31.38BUSDvs all stocks (USD)
Trailing P/E
21.28xvs Medical Instruments & Supplies peers
Forward P/E
16.78xvs Medical Instruments & Supplies peers
PEG Ratio
9.19xvs Medical Instruments & Supplies peers
Price to Sales (TTM)
5.66xvs Medical Instruments & Supplies peers
Price to Book (MRQ)
4.86xvs Medical Instruments & Supplies peers
Enterprise to Revenue
5.55xvs Medical Instruments & Supplies peers
Enterprise to EBITDA
14.97xvs Medical Instruments & Supplies peers
Gross Margin
58.84%vs Medical Instruments & Supplies peers
Profit Margin
26.95%vs Medical Instruments & Supplies peers
Operating Margin
30.86%vs Medical Instruments & Supplies peers
Return on Assets (TTM)
14.00%vs Medical Instruments & Supplies peers
Return on Equity (TTM)
24.27%vs Medical Instruments & Supplies peers
Revenue (TTM)
5.65BUSDvs all stocks (USD)
Revenue per Share (TTM)
38.85USDUpdated Sep 28, 2026Quarterly Revenue Growth
8.60%vs Medical Instruments & Supplies peers
Gross Profit (TTM)
3.48BUSDvs all stocks (USD)
EBITDA (TTM)
2.17BUSDvs all stocks (USD)
Net Income (TTM)
1.52BUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1.00%vs Medical Instruments & Supplies peers
Operating Cash Flow (TTM)
1.81BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
939.25MUSDvs all stocks (USD)
Forward Annual Dividend Rate
2.64USDUpdated Sep 28, 2026Forward Annual Dividend Yield
1.19%vs all stocks
Trailing Annual Dividend Rate
2.46USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
1.11%vs all stocks
5-Year Average Dividend Yield
0.88%vs all stocks
Payout Ratio
23.01%vs Medical Instruments & Supplies peers
Revenue
5.15BUSDFY2025 · Jun 30, 2025Cost of Goods Sold
2.09BUSDFY2025 · Jun 30, 2025Gross Profit
3.05BUSDFY2025 · Jun 30, 2025Operating Income
1.69BUSDvs all stocks (USD)
Pre-tax Income
1.68BUSDFY2025 · Jun 30, 2025Income Tax Expense
276.84MUSDFY2025 · Jun 30, 2025Net Income
1.40BUSDFY2025 · Jun 30, 2025EBIT
1.69BUSDFY2025 · Jun 30, 2025EBITDA (Income Statement)
1.93BUSDFY2025 · Jun 30, 2025Research & Development
331.28MUSDFY2025 · Jun 30, 2025Selling, General & Administrative
991.02MUSDFY2025 · Jun 30, 2025Net Income from Continuing Operations
1.40BUSDFY2025 · Jun 30, 2025Operating Cash Flow
1.57BUSDFY2025 · Jun 30, 2025Free Cash Flow
1.48BUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
1.21BUSDFY2025 · Jun 30, 2025Income Tax Paid
214.01MUSDFY2025 · Jun 30, 2025Interest Paid
28.41MUSDFY2025 · Jun 30, 2025Starting Profit (CF Statement)
1.40BUSDFY2025 · Jun 30, 2025Depreciation & Amortization
235.81MUSDFY2025 · Jun 30, 2025Stock-based Compensation
91.66MUSDFY2025 · Jun 30, 2025Change in Accounts Receivable (CF)
-76.68MUSDFY2025 · Jun 30, 2025Change in Other Assets/Liabilities
-80.17MUSDFY2025 · Jun 30, 2025Capital Expenditures
-89.86MUSDFY2025 · Jun 30, 2025Net Intangibles (CF)
-10.78MUSDFY2025 · Jun 30, 2025Net Acquisitions
-139.25MUSDFY2025 · Jun 30, 2025Purchase of Investments
-6.42MUSDFY2025 · Jun 30, 2025Sale of Investments
46.26MUSDFY2025 · Jun 30, 2025Net Investing Cash Flow
-189.27MUSDFY2025 · Jun 30, 2025Long-term Debt Issuance
0.00USDFY2025 · Jun 30, 2025Long-term Debt Payments
-40.00MUSDFY2025 · Jun 30, 2025Common Stock Repurchase
-300.02MUSDFY2025 · Jun 30, 2025Common Dividends Paid
-310.88MUSDFY2025 · Jun 30, 2025Other Financing Charges
-29.79MUSDFY2025 · Jun 30, 2025Net Financing Cash Flow
-606.25MUSDFY2025 · Jun 30, 2025Shares Outstanding
144.24MSharesUpdated Sep 28, 2026Float Shares
143.36MSharesUpdated Sep 28, 2026Shares Short
14.20MSharesUpdated Sep 28, 2026Short Ratio
10.58daysvs all stocks
Short % of Shares Outstanding
11.35%vs all stocks
% Held by Insiders
0.50%vs all stocks
% Held by Institutions
71.24%vs all stocks
Total Cash (MRQ)
1.47BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
10.19USDUpdated Sep 28, 2026Total Debt (MRQ)
825.92MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1254xvs Medical Instruments & Supplies peers
Current Ratio (MRQ)
3.10xvs Medical Instruments & Supplies peers
Book Value per Share (MRQ)
45.66USDUpdated Sep 28, 2026Total Assets
8.17BUSDvs all stocks (USD)
Total Current Assets
3.51BUSDFY2025 · Jun 30, 2025Total Liabilities
2.21BUSDFY2025 · Jun 30, 2025Total Non-current Assets
4.67BUSDFY2025 · Jun 30, 2025Total Non-current Liabilities
1.19BUSDFY2025 · Jun 30, 2025Total Current Liabilities
1.02BUSDFY2025 · Jun 30, 2025Cash & Cash Equivalents
1.21BUSDFY2025 · Jun 30, 2025Accounts Receivable
939.49MUSDFY2025 · Jun 30, 2025Inventory
927.71MUSDFY2025 · Jun 30, 2025Accounts Payable
278.16MUSDFY2025 · Jun 30, 2025Short-term Debt
40.41MUSDFY2025 · Jun 30, 2025Deferred Revenue
166.03MUSDFY2025 · Jun 30, 2025Other Current Liabilities
2.69MUSDFY2025 · Jun 30, 2025Long-term Debt
811.41MUSDFY2025 · Jun 30, 2025Other Non-current Liabilities
141.52MUSDFY2025 · Jun 30, 2025Common Stock (Book)
761.00KUSDFY2025 · Jun 30, 2025Retained Earnings
6.08BUSDFY2025 · Jun 30, 2025Total Shareholders' Equity
5.97BUSDvs all stocks (USD)
Treasury Stock
2.07BUSDFY2025 · Jun 30, 202552-Week Low
180.27USDUpdated Sep 28, 202652-Week High
284.87USDUpdated Sep 28, 202652-Week Change
-18.10%vs all stocks
Beta
0.7660xvs all stocks
50-Day MA
220.71USDUpdated Sep 28, 2026200-Day MA
226.45USDUpdated Sep 28, 2026Avg 10-Day Volume
1.37MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.35MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
10.43USDUpdated Sep 28, 2026Other Income / Expense
-13.94MUSDFY2025 · Jun 30, 202510 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 24.3%, higher than 95% of its Medical Instruments & Supplies peers (median 5.7%)Significant
Return on equity: 0.24Industry median: 0.06Industry P95: 0.23Peers compared: 109
Financial Health
Altman Z-Score 11.42: safe zoneNotable
Altman Z-Score: 11.42
High structural barrier to entryNotable
Barrier to Entry: 0.55
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Scale
Market cap is $32.02B, higher than 95% of all stocks globallySignificant
Market cap (USD): 32,024,011,932Global P95: 25,554,966,472.502
Revenue is $5.65B, above the global median of $548.88MNotable
Revenue (USD): 5,653,443,072Global Median: 548,883,780.48
Levered free cash flow is $939.25M, above the global median of $18.73MNotable
Levered free cash flow (USD): 939,248,256Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
CGN Power Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Vulcan Materials Company
Tier 1ProductionThroughput-Bound ConversionFlowRule
Gree Electric Appliances Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Venture Global Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRisk
JSW Steel Limited
Tier 1ProductionThroughput-Bound ConversionFlowRisk
Piotech Inc.
Tier 1ProductionThroughput-Bound ConversionSenseMakingFlow
Yuanjie Semiconductor Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowSenseMaking
BOE Technology Group Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Avary Holding (Shenzhen) Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Alcon Inc.
Tier 1ProductionThroughput-Bound ConversionRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Harmony Biosciences Holdings, Inc.
10 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Games Workshop Group PLC
10 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Catalyst Pharmaceuticals Inc.
10 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin